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Rapport de synthèse 
DEVENIR NEURO-DEVELOPPEMENTAL DE NOUVEAU-NES 
TRAITES PAR DU SULFATE DE MAGNESIUM POUR 
UNE HYPERTENSION PULMONAIRE PERSISTANTE 
L'hypertension pulmonaire persistante du nouveau-né (HTPP) est un trouble de l'adaptation 
post-natale de la circulation pulmonaire caractérisé par une défaillance de la diminution normale 
des résistances vasculaires pulmonaires, accompagné d'un shunt droite-gauche, résultant en 
une hypoxémie profonde. C'est une pathologie sévère nécessitant des soins intensifs avec un 
risque augmenté de handicaps neurologiques chez les survivants. 
Le traitement de l'HTPP du nouveau-né inclut une ventilation mécanique ainsi que différents 
agents pharmacologiques pour dilater les vaisseaux pulmonaires, dont le sulfate de magnésium 
(MgS04) à hautes doses par voie intraveineuse et le monoxyde d'azote par voie inhalée (iNO). 
Le MgS04 est une alternative thérapeutique de l'HTPP du nouveau-né avec peu d'effets 
secondaires et une mortalité basse. Il a aussi été démontré que le MgS04 est un traitement de 
l'HTPP du nouveau-né autant efficace que le iNO et moins coûteux. 
Des études sur le suivi neuro-développemental de nouveau-nés avec HTPP traités selon 
différentes méthodes ont été publiées reportant des taux élevés de handicaps majeurs et 
mineurs. Plus récemment, des études de suivi après traitement par iNO ont montré des taux 
plus bas qu'avec des traitements antérieurs. Le devenir neuro-développemental à long terme 
d'enfants traités avec du MgS04 n'a pas été documenté. 
Le but de cette étude est de décrire le développement des enfants qui ont présenté une HTPP 
traitée seulement avec du MgS04 , de reporter l'incidence de handicaps majeurs et mineurs, et 
de les comparer à un groupe contrôle d'enfants sains du même âge ainsi qu'aux données de la 
littérature. 
La population consiste en 33 nouveau-nés traités pour une HTPP avec seulement du MgS04 
(groupe étude) et 32 nouveau-nés à terme sains (groupe contrôle). Un suivi neuro-
développemental standardisé et approfondi a été effectué aux âges clés de 18 mois et 5 ans. 
Les taux de handicaps majeurs à 18 mois et 5 ans dans le groupe étude étaient de 6% et 
11,4% respectivement, et de 0% aux deux âges dans le groupe contrôle. Les taux de handicaps 
mineurs aux mêmes âges étaient de 3% et 26,9% pour le groupe étude, et de 0% et 26, 1 % 
pour le groupe contrôle. Les quotients développementaux moyens à 18 mois étaient de 106,6 
(DS 1 ,6) dans le groupe étude et de 118,3 (DS 1 ,0) dans le groupe contrôle (P < 0,001 ). L'index 
général intellectuel en âge préscolaire était de 112.6 (DS 3. 7), respectivement de 119.3 
(DS 3.1 ), sans différence significative entre les deux groupes. 
A 18 mois, les taux de handicaps majeurs et mineurs dans les groupes études et contrôle 
étaient de 6% et 3%. Dans la littérature, des taux entre 0% et 33% ont été décrits. A cet âge, il y 
avait une différence significative pour tous les scores du test de Griffiths, même en tenant 
compte du status socio-économique de la famille. Ceci suggère un léger retard du 
développement global et non une altération spécifique. Ces différences n'étaient plus 
significatives en âge préscolaire, suggérant un rattrapage développemental. Le taux de 
handicaps majeurs en âge préscolaire pour le groupe étude était de 11.5%, sans aucune 
infirmité motrice cérébrale. Ces résultats correspondent à ceux d'études de suivi après d'autres 
traitements jusqu'à l'âge de 24 mois avec des taux variant de 0% à 15%. Le taux de handicaps 
mineurs était de 26.9% dans le groupe étude et de 26.1 % dans le groupe contrôle, sans 
différence significative entre les deux groupes. L'incidence de handicaps mineurs dans le 
groupe étude était plutôt élevée en comparaison aux données de la littérature (6 à 22% à 6 
ans). Une explication possible est que nous avons considéré des problèmes de langage et de 
comportement comme handicaps mineurs. Ceci suggère une différence méthodologique et non 
une plus mauvaise issue dans nos deux groupes. Les évaluations cognitives des enfants des 
deux groupes se trouvaient dans la norme, ce qui est aussi le cas dans la littérature. 
En conclusion, cette étude longitudinale non randomisée d'enfants traités avec du MgS04 seul 
pour une HTPP sévère ne montre pas de conséquences sur le devenir neuro-développemental 
à long terme. Cette étude le démontre pour la première fois. Malgré le fait que iNO soit le 
traitement actuellement recommandé pour l'HTPP du nopuveau-né, le MgS04 reste largement 
utilisé, en particulier dans des pays en voie de développement. L'absence de complications 
neuro-développementales majeures à long terme permet de considérer l'administration du 
MgS04 pour le traitement de l'HTPP du nouveau-né en cas de non réponse ou d'inaccessibilité 
au iNO. 
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Neuro-developmental follow-up of neonates 
treated with magnesium sulfate for persistent 
pulmonary hypertension 
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Abstract. Persistent pulmonary hypertension of the newborn (PPHN) is a Jife threatening condition associated with an increased 
risk of neurological impairment. Magnesium sulfate (MgS04) is an alternative and low cost treatment for PPHN. Despite more 
appropriate and available therapies MgSQ4 is still widely used, especially in developing countries, but long-term follow-up is 
unknown. In a retrospective controlled study we evaluated whether MgS04 therapy for PPHN was associated with increased 
neuro-developmental impairments at follow-up, as compared to a control group. Population consisted of 33 infants treated for 
PPHN with MgS04 only (study group) and 32 healthy term infants (control group). Extensive neuro-developmental follow-up 
examination was performed at 18 months and 5 years of age. Rate of major impairments and minor impairments were evaluated 
and compared to the literature. 
The rates of major impairments in the study group at 18 months and 5 years were 6% and 11.4%, respectively, and 0% at both 
ages in the contrai group. The rates of minor impairments at the same ages were 3% and 26.9% for the study group, and 0% and 
26.1 % for the control group. Mean developmental quotients at 18 months were l 06.6 (SD 1.6) in the study group and 118.3 (SD 
1.0) in the control group (p < 0.001). General intellectual index at preschool age was not significantly different between the two 
groups. Treatment with MgS04 does not increase the rate of disability, as compared to other treatments for PPHN. 
Keywords: Persistent pulmonary hypertension of the newborn, magnesium sulfate, neuro-developmental follow-up 
1. Introduction 
Persistent pulmonary hypertension of the newborn 
(PPHN) is a pulmonary vascular disorder characterized 
by a failure of the normal postnatal fa]] in pulmonary 
vascular resistance which leads to persisting right to 
left shunts across the fetal channels and resultant hy-
poxemia [28]. Newborn infants with PPHN are at risk 
for severe hypoxemia and its complications, includ-
ing death, chronic lung disease, and abnormal neuro-
cognitive outcome. This condition occurs in nearly-
term, term, and mostly post-term newborns. Based on 
*Corresponding author: Dr. J.-F. Toisa, Division ofNeonatology, 
Pediatric Department, University Hospital CHUV, 1011 Lausanne, 
Switzerland. Tel.: +41 21 314 36 92; Fax: +41 21 314 34 77; E-mail: 
Jean-Francois.Tolsa@chuv.ch. 
a recent survey, PPHN incidence is 1.9 per 1000 live 
births with a wide variation observed among centers 
(0.43-6.82 per 1000 live births) [53]. 
Different risk factors and etiologies have been asso-
ciated with PPHN such as perinatal asphyxia, aspira-
tion of clear, bloody or meconial amniotic fluid, severe 
infections and hyaline membrane disease. Major mal-
formations like diaphragmatic hernia and pulmonary 
hypoplasia are also associated with PPHN. 
Associated morbidities and mortality are very vari-
able and depend mainly on underlying etiologies and 
the type of treatments. The mortality rate is estimated 
at 11 % ranging between 4% and 33% [53]. 
Different treatments have been proposed and re-
viewed [29,54]. Besides mechanical ventilation, va-
sodilator agents are administered intravenously (Tola-
zoline, Prostacyclin, Magnesium sulfate) or via inhala-
1934-5798/08/$17.00 © 2008-IOS Press and the authors. Ail rights reserved 
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tion like nitric oxide (iNO) or prostacyclin. Extracor-
poreal membrane oxygenation (ECMO) is still recom-
mended in case of failure of these therapies. Before the 
era of iNO, high doses of magnesium sulfate (MgSO 4) 
have been proposed in preterm and term newboms [ 1, 
50,56]. MgS04 has been shown to be effective, with 
few side effects and low mortality [50]. Despite the 
fact that iNO is now recognized as the first line treat-
ment for PPHN [11], MgS04 therapy is still widely 
used, especially in developing countries where iNO is 
not available [8,14,15,41]. Recently, MgS04 has also 
been shown to be as safe in treating moderate PPHN as 
iNO, and cheaper [42]. Neuro-developmental follow-
up studies of infants with PPHN following different 
kinds of treatments (hyperventilation, vasodilators and 
ECMO) have been published during the last 20 years 
reporting a high rate of minor and major handicaps (5, 
10,24,31,46,55]. More recently, follow-up studies of 
newbom infants treated with iNO showed that the oc-
currence of minor and major handicaps was lower than 
with previous treatments [17 ,34,49]. Besides its use for 
the treatment of PPHN, MgS04 has also been evaluated 
for its neuroprotective effects during fetal or neonatal 
hypoxic-ischemic injury. Both protective and delete-
rious effects have been reported in animal studies [22, 
45] as well as in human studies [26,33]. 
Newborn infants suffering from PPHN are in a con-
dition of hypoxia-ischemia, which may have effects on 
the brain and be influenced by high doses of MgSO 4. 
However long-term effects on neurodevelopment of 
MgS04 as a treatment for severe PPHN have not been 
reported so far [25]. 
The purpose of this study is to report the incidence of 
major and minor handicaps and to describe the devel-
opment of children who presented with PPHN treated 
only with MgS04, as compared to a control group of 
healthy children of the same age and to the data of the 
literature. 
2. Methods 
2.1. Population 
Population consisted in two groups of patients. A 
"study" group of infants who had presented PPHN 
treated with MgS04 and a "contrai" group of healthy 
newborns born during the same period. Written and 
oral information were given to parents about ourfollow-
up program, which has been approved by the ethics 
committee for clinical research of the University of 
Lausanne. 
2.2. Study group 
Eighty-five newborns admitted to our Neonatal In-
tensive Care Unit with severe persistent pulmonary hy-
pertension were treated with MgS04 between January 
1, 1992 and December 31, 1998 as described previous-
ly [50]. This treatment was offered as a compassion-
ate therapy to the parents while no other better treat-
ment was available in our unit at that time. Briefly, 
a loading dose of 200 mg/kg MgS0 4 was given intra-
venously over 20 minutes, followed by a continuous 
infusion of20-150mg/kg/hourto obtain a total magne-
sium bJood concentration between 3.5 and 5.5 mmoJ/I. 
Cardiac output was supported with dopamine and/or 
dobutamine infusion. Duration of magnesium therapy 
was between 3 to 5 days. No side effects were ob-
served. The diagnosis of PPHN was considered in the 
presence of a persistent hypoxemia (post-ductaJ par-
tial arterial pressure in oxygen (Pa02) < 50 mmHg or 
<6.67 KPa) under respiratory support with a fraction 
of inspired oxygen (Fi02) of 1.0 and maximal conven-
tional ventilation. PPHN was also considered under 
similar respira tory support in the presence of persistent 
hypoxemia out of proportion to the degree of Jung dis-
ease on the chest radiograph and/or an important labili-
ty of oxygenation with great variations in PaO 2 without 
changes in ventilator settings. PPHN was confirmed 
by echocardiography in ail patients and cardiac heart 
disease was ruled out. 
Among the 85 infants, 33 were excluded, 21 because 
they were on other therapies before initiating treatment 
with MgS04 (9 intravenous tolazoline and/or hyper-
ventilation, 12 iNO), and 12 because of the presence 
of major malformations including diaphragmatic her-
nia and Jung hypoplasia associated with various clini-
cal syndromes. Among the 52 newboms treated with 
MgS04 only, 4 died in the neonatal period (7.7%) and 
1 after discharge from sudden infant death. Forty-
seven newborns were finally included in our neuro-
developmentaJ follow-up program. 
Among the 47 survivors, 14 were Jost to follow-up, 
33 (70.2%) were examined atour neuro-deveJopmental 
clinicat 18 months and 26 (55.3%) were controlled a 
second time at preschooJ age (3.5 to 5 years). 
2.3. Control group 
Thirty-six infants, al! full-term newboms (gestation-
aJ age Ç37 weeks), bom in the matemity of the Univer-
sity Hospital in Lausanne, were enrolled in our follow-
up program from January 1 to December 31, 1998. 
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Infants from mothers with multiple pregnancies, dif-
ficulties during pregnancy or delivery, somatic abnor-
malities, or from parents with psychiatrie prablems 
were excluded. Thirty-two children (88.9%) were ex-
amined at 18 months and 23 (63.9%) at preschool age. 
2.4. Neonatal data 
Neonatal history, as well as demographic and social 
data, were retraspectively collected for each patient. 
Clinical data included birth characteristics, neonatal 
pathologies associated with the development of PPHN, 
and treatment including ventilatory settings during the 
neonatal hospitalization. The !owest Pa02, the Oxy-
genation Index (OI) and the Alveolo-arterial Oxygen 
Difference (A-aD02) were registered as severity in-
dices before the introduction of MgS04. Pathologies 
associated with the development of PPHN were respi-
ratory distress syndromes following meconium aspira-
tion, pneumothoraces, infection, asphyxia, and hyaline 
membrane disease. 
Socio-economic status (SES) was calculated by a 
six-point scale of parental occupation, a score of 1 
representing an academic position and a score of 6, 
unskilled work [30]. 
2.5. Follow-up procedure 
Children were examined by pediatricians at 18 
months and at pre-school age by pediatricians and psy-
chologists not involved in the initial neonatal care. 
Follow-up examination at 18 months consisted of a 
detailed neuralogical examination according to Amiel-
Tison [3] and of an assessment of psychomotor devel-
opment using the Griffiths scales [23]. The evaluation 
of vision and hearing was a!so performed [48]. If nec-
essary, children were referred to an ophthalmo!ogist 
and/or for audiometric assessment. 
Follow-up examination at pre-school age included a 
comprehensive standardized neuralogical examination 
adapted from Touwen [52]. The evaluation of vision 
and hearing was performed as at 18 months. 
Cognitive abilities were evaluated with the McCarthy 
Scale of Children's Abilities [38] administered by a 
psychologist who also evaluated clinically the language 
and behavioral characteristics according to the Diag-
nostic and Statistical Manual Disorders (DSM IV) [2]. 
2.6. Outcome parameters 
At 18 months, outcome parameters included major 
impairments, minor impairments and psychomotor de-
velopment. Major impairments consisted in develop-
mental delay with a developmental quotient below 70, 
cerebral palsy (CP), neura-sensory hearing Joss (au-
ditory threshold above 60 dB), severe visual impair-
ment and epilepsy. Minor impairments included non-
CP neuralogical abnormalities and sensorial disorders 
such as minor hearing Joss, squint and refractive errors. 
Psychomotor development was evaluated by the 5 Grif-
fiths sub-scores, Locomotor, Personal-Social, Hearing 
and Speech, Eye-Hand Coordination and Performance, 
and the global Development Score (DQ). Each score 
was standardized for an expected value of 100 with a 
Standard Deviation (SD) of 15. 
At preschool age, outcome parameters included ma-
jor impairments, minor impairments and cognitive abil-
ities. Major impairments were defined as at 18 months, 
with intelligence quotient below 70. Minor impair-
ments included neura-motor signs, minor hearing Joss, 
squint, refractive errors, language and behavior disor-
ders. For each child, a General Intellectual Index (GII) 
with scores in the five subsca!es of the McCarthy Scale 
of Children 's Abilities was calculated. GII was stan-
dardized for an expected value of 1 OO (SD of 16) and 
the subscale scores (Index) for an expected value of 50 
(SD of 10). 
2. 7. Statistics 
Ail the informations were registered and analyzed us-
ing the Statistical Package for Social Science software 
(SPSS, version 10.0). Univariate analysis of variance 
(ANOVA) and the Chi-square test with Yates correc-
tion, or the Fischer's test (for small numbers) were per-
formed for comparisons between groups. Multivariate 
analysis of variance (MANOVA) was chosen when one 
independent variable was to be contralled. The thresh-
old for statistical significance was considered when p 
value was below 0.05. 
3. Results 
Birth characteristics of the 65 patients (33 treated 
with MgS04, 32 contrai) who were followed are sum-
marized in Table 1. 
There were no statistical differences in the neonatal 
characteristics between the study and the contrai graups 
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Table 1 
Birth characteristics 
B irth characteristics 
Males(%) 
Gestational age (weeks) 
Birth weight (grams) 
Inborn 
Apgar at 1 minute 
Apgar at 5 minutes 
SES index (Largo) 
Study group 
(n = 33) 
20 (60,6) 
37.1 (2.3) 
2905 (570) 
10 (30) 
7.1(2.1) 
7.9(1.9) 
3.2(1.2) 
Control group 
(n = 32) 
18 (56,3) 
39.8 (1.1) 
3303 (466) 
32 (100) 
8.8 (1.4) 
9.3 (0.8) 
2.3(1.1) 
p value 
NS 
NS 
NS 
<0.001 
<0.001 
<0.001 
0.004 
Values represent means (standard deviations in parenthesis), except 
for males expressed in actual numbers. 
except for the APGAR scores at 1 and 5 minutes which 
were significantly lower in the study group (p < 0.001). 
The SES was significantly higher in the study group 
(p = 0.004), corresponding to a lower socio-economic 
status. 
3.1. Neonatal course in the study group 
Pathologies associated with the development of 
PPHN consisted for the 33 children followed-up in 12 
(36%) aspiration syndromes, 9 (27%) pneumothoraces, 
12 (36%) sepsis/pneumonia, 7 (21 % ) neonatal asphyx-
ia, and 4 (12%) hyaline membrane disease. Before the 
introduction of MgS0 4 , ail patients were under maxi-
mal conventional ventilation with a mean airway pres-
sure of 16.7 (SD 3.0) cm H 20 and an Fi02 of1.0. The 
patients were severely ill with a lowest mean Pa02 of 
41.5 (SD 11.5) mmHg, an OI of 45.2 (SD 21.2) and 
an a-A D02 of 626.5 (SD 14.8) mmHg. Ali newboms 
were treated with a potentially ototoxic agent, 31 (94%) 
with furosemide and 33 ( 100%) with gentamicin. Mean 
duration of MgS0 4 therapy was 3.4 (SD 1.4) days. 
Conventional ventilation was necessary during a mean 
of 7 .8 (SD 4.2) days and total oxygen supplementation 
during a mean of 17 .9 (SD 30.J) days. They were ail 
discharged from hospital free of any treatment after a 
mean hospital stay of 31 (SD 26) days. 
The neonatal course of the 14 infants lost to follow-
up did not differ from that of the 33 children followed-
up except for the mean airway pressure which was 
significantly higherfor the followed group, respectively 
16.7 (3.0) and 13.9 (2.5) cm H 20, p < 0.03. 
3.2. Outcome at 18 months 
Thirty-three children were examined at 18 months 
of age in the study group and 32 in the control group. 
The age of the infants at the follow-up evaluation was 
19.7 months (SD 2.1; range 17.5-25.0) for the study 
group and 18.4 months (SD 0.5; range 18.0-19.5) for 
the control group. 
Most of the infants in the study group and ail con trois 
were neurologically normal at 18 months. In the study 
group, major impairments were detected in 2 infants 
and min or impairments in 1 infant. Among the children 
with major impairments, one presented a severe visual 
impairment due to a bilateral optical atrophy, which was 
considered to be unrelated to neonatal history, and the 
other one presented a severe sensorineural hearing Joss 
in the context of a Streptococcus B sepsis complicated 
by multiple pneumothoraces and PPHN. The child with 
minor impairment had a squint. 
The mean DQ of infants without major impairment 
was of 106.6 (SE 1.6) in the study group (n = 31) 
and of 118.3 (SE 1.0) in the control group (n = 32). 
The difference between the 2 groups was statistically 
significant (F: 38.82; p < 0.001) and remained sig-
nificant even when the SES was controlled (F: 33.01; 
p < 0.001). A normal distribution was observed for the 
two groups with a shift on the left for the study group 
(Fig. 1 ). This shift is congruent with the difference 
observed for the means. 
The components of the 5 subscales of the Griffiths 
scale were analyzed separately for the study and the 
control groups. The means of the subscales and stan-
dard deviations are illustrated in Fig. 2. Ali the scores 
were significantly lower for the study group, even when 
the SES was controlled. 
3.3. Outcomes at preschool age 
Preschool age evaluation was performed between 3,5 
and 5 years in 26 children in the study group and 23 
in the control group. Seven children from the study 
group were lost for this second follow-up visit. Ac-
cording to their parents and/or pediatrician they were 
ail developing normally. 
The age of the children at the preschool follow-up 
evaluation was 51.1 months (SD 9.2) for the study 
group and 45.2 months (SD 0.9) for the control group. 
Most children of both groups were neurologically 
normal at preschool age. The incidence of major im-
pairments at preschool age was of 11.5%. A third child 
of the study group presented a major impairment. This 
child developed at the age of 3.5 years epilepsy and 
mental retardation (GII<50) of probable genetic etiol-
ogy. During the neonatal period he never had seizures 
and cerebral ultrasound were normal. No child in the 
control group developed a major impairment. 
20 
n 
15 
10 
5 
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[il control group (n;32) 
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DQ 
Fig. 1. Developmental Quotient (DQ) at 18 months (children without major impairment). 
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Fig. 2. Oriffith's subscales at 18 months. 
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An increase in minor impairments was observed be-
tween 18 months and preschool age in both groups. Mi-
nor impairments were observed in 7 children (26.9%) 
in the study group and in 7 children (30.4%) in the 
control group. 
Concerning the cognitive competences, the means 
for the GII for the study and the control groups (infants 
with major impairments excluded) were of 112.6 (SD 
3.7) and 119.3 (SD 3.1), respectively. These scores 
were not statistically different whether the SES was 
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10 
n Ill study group (n=20) 
[l] contrai group (n=23) 
70-79 80-89 90-99 100-109 110-119 120-129 130-139 140-149 
GU 
Fig. 3. General Intellectual Index (Gll) at preschool age (children without major impairment). 
controlled (F: 0.101) or not (F: 2.029). 
Figure 3 illustrates the distribution of the scores for 
the General Intellectual Index in the two groups. A 
normal distribution was observed for the two groups 
with a shift on the left for the study group. However the 
overlap of the two groups increased between 18 months 
and preschool age and statistical differences were no 
longer observed. 
The 5 subscales of the McCarthy scale of children's 
abilities were analyzed separately for the study and 
the control groups and are illustrated in Fig. 4. When 
the SES is not controlled, the scores for the quantita-
tive index (F: 4.16; p < 0.05) and the memory index 
(F: 5.44; p < 0.05) are significantly different between 
the two groups. This is no longer the case when the 
SES is taken into account in a MANOVA analysis. 
4. Discussion 
Magnesium sulfate is an alternative and low cost 
treatment for PPHN. Despite more appropriate and 
available therapies such as iNO or prostacyclin, high 
doses of MgS04 are stîll widely used, especially in de-
veloping countries [8, 14, 15,41]. At high serum con-
centrations, magnesium is a muscle relaxant and va-
sodilatory agent. Animal studies have shown that mag-
nesium can prevent and reduce hypoxia-induced pul-
monary hypertension [12,37]. Substantial evidence 
suggests that magnesium may modulate vasoactivity by 
affecting the influx of extracellular Ca 2+. Inhibition of 
voltage-dependent Ca2+ channels by magnesium may 
be one of the mechanisms by which the pulmonary 
vasculature relaxes during intravenous treatment with 
magnesium [51]. It may also act through effects on 
the metabolism of prostaglandins, suppression of the 
release of catecholamines, activation of adenyl cyclase, 
and reduction of the responsiveness of smooth muscles 
to vasopressors [54]. 
Neuro-developmental outcome of infants treated for 
PPHN with varions therapies have been extensively re-
ported [4,6,19,31,34,36,44,49] but long-term outcome 
of infants treated with high doses of magnesium is not 
documented [25]. Moreover, the effects of high doses 
of magnesium on fetuses in case of maternai therapy 
for pre-eclampsia [13,35,39,40] or in newboms to pre-
vent adverse outcomes of severe birth asphyxia [ 16,26, 
32] are controversial. We therefore aim to describe the 
long term follow up of infants treated with high dos-
es of magnesium as a sole therapy for severe PPHN 
compared to a control group and the literature. 
Our population of newborns treated with high doses 
of MgS04 consisted in 52 neonates among which 4 
died in the neonatal period (mortality rate 7.7%). This 
mortality rate is comparable to recent data with other 
treatments [27 ,49]. 
At 18 months, 2 children (6 %) had major impair-
ments and 1 (3%) a minor impairment. Widely di-
vergent incidences of impairments are reported in the 
literature. They vary between 0% [6] and 33% [31], 
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Fig. 4. McCarthy subscales at preschool age. 
reftecting the difficulty in comparing outcome data of 
follow-up studies with methodological differences. 
Mean DQ scores of the study and the control groups 
observed at 18 months were ail distributed in the nor-
mal range. There was a significant difference between 
the two groups on ail the scores of the Griffith's test, 
even when the socio-economic status of the family was 
controlled. This suggests a minor global developmen-
tal delay and not a specific developmental alteration. 
These differences are difficult to explain and were no 
longer significant at preschool age, suggesting a devel-
opmental catch-up. We postulate that the minor devel-
opmental delay observed at 18 months might be in re-
lation to prolonged neonatal hospitalization. An inter-
mediate developmental evaluation at 6 months would 
have been useful to confirm this hypothesis. 
Our results are in agreement with studies reporting 
follow-up after other treatments until the age of 24 
months using the Bayley test which includes a mental 
and a psychomotor scale [6,7, 19,24,44]. 
Our rate of major impairments at preschool age is 
11.5%, with no cerebral palsy. Follow-up studies of 
children treated with various therapies for PPHN report 
different rates of major impairment at preschool age: 
after hyperventilation 0% [4], after hyperventilation 
and tolazoline 7.5% [47], after tolazoline alone 14.3% 
to 14.8% [10,36], and finally after ECMO the rates lie 
between 4 and 15% [9,20,21,46]. For inhaled NO, the 
actually recommended treatment, the reported rate of 
major impairment is 6.7% at 3 years [27]. Our results 
lie in the same range as these different studies. 
One particular outcome reported in the literature 
is the rate of hearing loss. It has been shown that 
sensori-neural hearing loss among children with severe 
neonatal respiratory failure is related to the ototoxic 
drugs used for supportive therapy (diuretics, amino-
glycosides and neuromuscular blockers), and not to 
the severity of the disease or the treatment of the res-
piratory failure [43]. In our population, although ail 
the children were treated with aminoglycosides and/or 
furosemide, we observed only 1 patient with hearing 
loss (3.8%). Neuromuscular blockers were not used 
since high serum concentrations of magnesium already 
in duce some neuromuscular blockade [ 18]. 
At preschool age, 7 (26.9%) children presented mi-
nor impairments in the study group, and 6 (26.1 %) in 
the control group. There was no significant difference 
between the two groups. We also considered language 
and behavior disorders like hyperactivity as minor im-
pairments, which are not considered as such in most 
follow-up studies. 
Our incidence of minor impairments is quite high in 
comparison with published data. In previous reports 
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the incidence varied from 6.7% to 22% between 1 to 
6 years [4,21,27,36]. A possible explanation for our 
higher rate is that we also considered language and 
behavior disorders as minor impairments. The rate 
of minor impairments was high in the control group 
as well. This suggests a methodological difference 
between our and the previous studies, and not a poorer 
outcome in our two groups. 
Cognition in pre-school age, assessed by the 
McCarthy Scales, was in the normal range both for the 
study and the control group, with no statistical differ-
ence. Cognitive outcome in the literature, using differ-
ent tests, reported scores in the normal range as well [4, 
10,20,27 ,36,46,47]. 
In conclusion, this longitudinal non-randomized 
study of children treated with magnesium alone for se-
vere PPHN shows no detrimental effect of this treat-
ment on long-term neuro-developmental outcome. It is 
the first time to our knowledge that this is demonstrat-
ed. Severity of outcome in our population was relat-
ed to the severity of disease and associated conditions, 
as well as to genetic conditions. Despite the fact that 
iNO is the actual recommended treatment for PPHN, 
MgS04 is still widely used, especially in developing 
countries as recent literature suggests. The absence of 
detrimental neuro-developmental effects deems it safe 
to administer when there is no other choice. 
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